Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Waverley PharmaTSXV:WAVE 3-Year ROIIC % is 21.68 as of Dec. 2025, which is 60% below its 10-year median of 53.95. The stock has 5 warning signs investors should review. Among 1,320 Biotechnology companies, Waverley Pharma ranks better than 65.61% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Waverley Pharma's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 21.68%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Waverley Pharma's 3-Year ROIIC % or its related term are showing as below:
TSXV:WAVE's 3-Year ROIIC % is ranked better than 65.61% of 1320
companies
in the Biotechnology industry
Industry Median: -4.835
vs TSXV:WAVE: 21.68
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Waverley Pharma 3-Year ROIIC % Related Terms
Waverley Pharma 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Waverley Pharma's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSXV:WAVE vs VRTX, REGN, RVMD: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Waverley Pharma's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Waverley Pharma 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Waverley Pharma's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Waverley Pharma's 3-Year ROIIC % falls into.
Waverley Pharma's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -0.349 (Dec. 2025) - -0.638 (Dec. 2022) )
/
( 4.088 (Dec. 2025) - 2.755 (Dec. 2022) )
=
0.289
/
1.333
=
21.68%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Waverley Pharma (TSXV:WAVE) has a 3-Year ROIIC % of 21.68 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Waverley Pharma and its competitors. This is 60% below median its historical median of 53.95. According to the industry distribution chart, Waverley Pharma ranks #454 out of 1320 companies in the Biotechnology industry, placing it in the top 34.4%.
Is Waverley Pharma's 3-Year ROIIC % too high?
Waverley Pharma's current 3-Year ROIIC % of 21.68 is 60% below median its 10-year median of 53.95. Based on the distribution chart, Waverley Pharma ranks #454 out of 1320 companies in the Biotechnology industry, which is above the industry midpoint.
How does Waverley Pharma's 3-Year ROIIC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Waverley Pharma ranks #454 out of 1320 companies for 3-Year ROIIC %. This puts Waverley Pharma in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Waverley Pharma and its competitors. Waverley Pharma's current 3-Year ROIIC % is 21.68, which is 60% below median its own 10-year median of 53.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Waverley Pharma stock overvalued right now?
Based on GuruFocus' analysis, Waverley Pharma (TSXV:WAVE) is currently considered Possible Value Trap. The stock's GF Value™ is C$0.07, compared to a current price of C$0.02 — trading 78.6% below its estimated fair value. The current 3-Year ROIIC % is 21.68, which is 60% below median its 10-year median of 53.95. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Waverley Pharma (TSXV:WAVE), the current 3-Year ROIIC % is 21.68 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Waverley Pharma Inc is a biopharmaceutical company. It is engaged in the research, development, and commercialization of human therapeutics focused on oncology. The company's product pipeline includes Bortezomib, Pemetrexed, Capecitabine, and Temozolomide, among others. The company operates in one business segment, the biopharmaceutical industry.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:WAVE has been successfully added to your 
